CN-122005870-A - Application of circAtp b in preparation of medicines for resisting myocardial infarction

Abstract

The invention relates to the technical field of biological medicines, in particular to an application of circAtp b in preparing medicines for resisting myocardial infarction. The invention discovers circAtp b for the first time that the invention has the effect of improving and treating myocardial infarction. The specific embodiment of the invention verifies that after the disturbance circAtp b is verified by a cell model experiment, the calcium steady state in the myocardial cells is disordered, and myocardial damage occurs, and verifies that the over-expression circAtp b can obviously reduce the occurrence of myocardial infarction by a mouse model experiment. Therefore, circAtp b can be used for preparing medicines for treating and/or improving myocardial infarction, and a new thought is provided for treating myocardial infarction.

Inventors

• ZHAO DANDAN
• CHENG XIN
• QIAO XIAOQIANG
• LI JINGGE
• Chen Rudi
• Tian Tianru

Assignees

• 河北大学

Dates

Publication Date

20260512

Application Date

20260413

Claims (10)

1. The application of the circAtpp 9b in preparing medicaments and/or pharmaceutical compositions for treating myocardial infarction is characterized in that the nucleotide sequence of circAtp b is shown as SEQ ID NO. 1.
2. 2. The application of the agent for over-expressing circAtp b in preparing medicaments and/or pharmaceutical compositions for treating myocardial infarction is characterized in that the nucleotide sequence of circAtp b is shown as SEQ ID NO. 1.
3. 3. The use of claim 2, wherein the agent that overexpresses circAtp b comprises a circAtp b overexpression vector or an overexpressed circAtp b lentivirus.
4. 4. A medicament and/or a pharmaceutical composition for treating myocardial infarction is characterized by comprising an agent for over-expressing circAtp b, wherein the nucleotide sequence of circAtp b is shown as SEQ ID NO. 1.
5. 5. The pharmaceutical and/or pharmaceutical composition of claim 4, wherein the agent that overexpresses circAtp b comprises a circAtp b over-expression vector or an over-expression circAtp b lentivirus.
6. The application of the circAtpp 9b in preparing medicaments and/or pharmaceutical compositions for improving myocardial infarction is characterized in that the nucleotide sequence of circAtp b is shown as SEQ ID NO. 1.
7. 7. The application of the agent for over-expressing circAtp b in preparing medicaments and/or pharmaceutical compositions for improving myocardial infarction is characterized in that the nucleotide sequence of circAtp b is shown as SEQ ID NO. 1.
8. 8. The use of claim 7, wherein the agent that overexpresses circAtp b comprises a circAtp b overexpression vector or an overexpressed circAtp b lentivirus.
9. 9. A drug and/or a drug composition for improving myocardial infarction is characterized by comprising an agent for over-expressing circAtp b, wherein the nucleotide sequence of circAtp b is shown as SEQ ID NO. 1.
10. 10. The pharmaceutical and/or pharmaceutical composition of claim 9, wherein the agent that overexpresses circAtp b comprises a circAtp b over-expression vector or an over-expression circAtp b lentivirus.

Description

Application of circAtp b in preparation of medicines for resisting myocardial infarction Technical Field The invention relates to the technical field of biological medicines, in particular to an application of circAtp b in preparing medicines for resisting myocardial infarction. Background Myocardial infarction (Myocardial infarction, MI) is the most critical clinical type of cardiovascular disease, being the leading cause of sudden cardiac death and heart failure. The pathological basis of MI is the rapid decrease or interruption of coronary blood flow, causing irreversible necrosis of myocardial cells in the corresponding blood supply area due to persistent ischemia and hypoxia. This pathological process often induces severe complications such as malignant arrhythmia, cardiogenic shock, acute heart failure, or even sudden cardiac death, and seriously endangers the life health and the quality of life of the patient. At present, clinical treatment strategies aiming at MI mainly comprise emergency percutaneous coronary intervention treatment, thrombolytic therapy, antiplatelet and lipid-regulating drug treatment and the like, and the core aims at dredging the artery related to infarction as soon as possible, thereby controlling the progress of the condition and limiting the expansion of the infarct area to a certain extent. However, despite the ongoing optimization of therapeutic strategies, significant limitations remain with respect to overall therapeutic efficacy, and patient prognosis and quality of life improvement are not yet ideal. Therefore, the method can deeply analyze key molecules in the occurrence and development processes of MI, find effective intervention targets capable of treating MI, and has important clinical significance. Circular RNA (circRNA) is a special non-coding RNA molecule, and is in a closed circular structure, and lacks a 5 '-end cap and a 3' -end poly (A) tail, so that the circular RNA is resistant to degradation of exonuclease, and has higher stability and half-life in cells, unlike traditional linear RNA. In recent years, a large number of circRNAs differentially expressed in the cardiovascular system have been identified, and their role in the pathogenesis of heart disease and their regulatory mechanisms have been gradually revealed. The research shows that circFndc b can regulate and control the expression of vascular endothelial growth factor to promote cardiac repair after myocardial infarction, circSamd b can regulate and control the expression in myocardial cells after myocardial infarction, and the overexpression circSamd4 can reduce oxidative stress injury and promote proliferation and repair of myocardial cells after myocardial infarction by reducing the generation of mitochondrial active oxygen. Together, these studies suggest that circRNAs plays a diverse regulatory role in the pathological course of MI. However, no therapeutic effect of circRNAs on myocardial infarction is reported. Disclosure of Invention The invention aims to provide an application of circAtp b in preparing medicines for resisting myocardial infarction, so as to solve the problems in the prior art. In order to achieve the above object, the present invention provides the following solutions: the invention provides an application of circAtp b in preparing a medicament and/or a pharmaceutical composition for treating myocardial infarction, wherein the nucleotide sequence of circAtp b is shown as SEQ ID NO. 1. The invention provides application of an agent for over-expressing circAtp b in preparation of a medicament and/or a pharmaceutical composition for treating myocardial infarction, wherein the nucleotide sequence of circAtp b is shown as SEQ ID NO. 1. Optionally, the agent that overexpresses circAtp b comprises a circAtp b overexpression vector or an overexpressed circAtp b lentivirus. The invention provides a medicament and/or a pharmaceutical composition for treating myocardial infarction, which comprises an agent for over-expressing circAtp b. Optionally, the agent that overexpresses circAtp b comprises a circAtp b overexpression vector or an overexpressed circAtp b lentivirus. The invention provides an application of circAtp b in preparing medicines and/or pharmaceutical compositions for improving myocardial infarction, wherein the nucleotide sequence of circAtp b is shown as SEQ ID NO. 1. The invention provides application of an agent for over-expressing circAtp b in preparation of medicines and/or pharmaceutical compositions for improving myocardial infarction, wherein the nucleotide sequence of circAtp b is shown as SEQ ID NO. 1. Optionally, the agent that overexpresses circAtp b comprises a circAtp b overexpression vector or an overexpressed circAtp b lentivirus. The invention provides a medicament and/or a pharmaceutical composition for improving myocardial infarction, which comprises an agent for over-expressing circAtp b. Optionally, the agent that overexpresses circAtp b comprises a